Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Dec 032018
 
Global Newswire on 12-3-2018 had the headline: “Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy” (https://finance.yahoo.com/news/geron-announces-overall-survival-data-212242622.html: obtained on 12-3-2018) and the article began the following way: “
“GlobeNewswireData Reporting Median Overall Survival of 29.9 Months in High-Dose Arm

Presented at the 60th American Society of Hematology Annual Meeting

MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) — Geron Corporation (GERN) today announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk myelofibrosis (MF) patients who are relapsed or refractory to a Janus Kinase (JAK) inhibitor, were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The oral presentation was made on December 3, 2018 by John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, and an IMbark clinical investigator.

‘The IMbark results suggest a meaningful survival outcome in this poor-prognosis, relapsed/refractory MF patient population where there are currently no approved treatments,’ said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer. ‘We plan to explore potential late-stage development opportunities for imetelstat in MF through discussions with experts in MF and regulatory authorities and expect to provide a decision regarding future development of imetelstat in this patient population by the end of the third quarter of 2019.’

Clinical Data Presentation

Title: Imetelstat is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels (Abstract #685)”

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

Louis DeCola, Jr.  © 2018                                    The Hygiology Post ®

 

 

Click on button for instructions to purchase any product with desired cryptocurrency below and/or tip for content comprising hundreds of posts. Thank You!

 

Bytecoin (BCN) Address: 29bxUxr7wa8AzP8tvkAJqT8S8R5XTdBwHce9hwPhWx9oMRrsd5hxFsqR1uxBuKvSejTYqVXC6TSe241KoxVg1sF2SXZ6Z9H

Verge (XVG) Address: DCF3g6Zj6g3NspfNeMs6JsEgCsAVmVmkg4

MaidSafeCoin/Safecoin (MAID) Address: Rtd6RWvA1xLFhHKYCfvk5dt7UsstdFcbfK